Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors
February 13, 2024 at 04:15 pm EST
Share
On February 7, 2024, John L. Bishop, a member of the Board of Directors of Veracyte, Inc., informed the Chair of the Board that he will retire at the end of his current term as director and not stand for reelection at the Company?s 2024 annual meeting of stockholders. Mr. Bishop will continue to serve on the Board until his term ends at the 2024 Annual Meeting.
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
VERACYTE, INC. 
